about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsPI3K/PTEN/AKT signaling regulates prostate tumor angiogenesisLithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cellsTumor refractoriness to anti-VEGF therapyParallel Aspects of the Microenvironment in Cancer and Autoimmune DiseaseVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsUnderstanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironmentRapalogs in cancer prevention: anti-aging or anticancer?Combination therapy for renal cell cancer: what are possible options?Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerAre VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Hypoxia promotes colon cancer dissemination through up-regulation of cell migration-inducing protein (CEMIP)Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabmicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancersGlucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.Capsaicin-induced activation of p53-SMAR1 auto-regulatory loop down-regulates VEGF in non-small cell lung cancer to restrain angiogenesis.Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.Drug resistance in cancer: principles of emergence and prevention.A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.Selective anti-cancer agents as anti-aging drugsInhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalkFailure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cellsCan we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in MelanomaA new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of RasCadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells.Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma modelMolecular damage in cancer: an argument for mTOR-driven agingActivating transcription factor 5 enhances radioresistance and malignancy in cancer cells.Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61.Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.
P2860
Q21183974-A38FCACE-D2F2-4187-A5D7-C665A07391F0Q23914949-98F213B2-E2CD-4172-8243-9640A4DEB348Q24617423-F824E004-07ED-4E57-83ED-A3EB8ED075ACQ26747678-51A8E55E-2613-470D-97F6-81B23E6A35B6Q26753174-3EE1B414-F85B-4042-B762-DED295D4D8CCQ26770678-CB7521E4-317A-4CB6-A12F-F4D721D7D626Q26774355-A0140044-3377-4E9A-A31F-0156CAF2768DQ26797292-19C72A95-50D3-4AA4-84C1-C767CE7E062EQ26852398-F1FD7014-E8BE-4D0B-8EEA-5CA439339DBBQ26866151-6BA44EFF-9068-4CAB-9737-AADA3015DDDFQ27011663-C77533CA-DDB1-4575-A158-146D1B136ED2Q28068654-87533097-3B87-4C28-A234-03B2DDFD2114Q28085104-8C70D829-AD31-47D6-B0F6-59BAF133113EQ30279300-47839CD9-99E1-4FB1-879D-EA93FB744968Q30919257-6C7067C2-20A4-4771-9E3C-2D60B5D58E96Q33397006-96310046-2A9D-4CDB-AB04-B2B52EFA8816Q33414685-C91F20D3-882A-4C1D-A2BA-63650939238BQ33418562-E09B6154-4673-4125-8CFD-755647682DA9Q33576814-6B9CEF31-4A87-492B-9AED-91B26DDB187CQ33688593-721C863F-FEA7-4889-951C-E09A02ABCDA8Q33698044-955B70A8-E128-4F9C-B0BA-8C0501428A37Q33754109-A993ACBE-7E51-45CB-910B-266E6878B26BQ33757046-83CE9853-A6A9-4324-9E37-E9479A2FBFE0Q33757101-C38DDC97-AEC7-4070-97BA-D09D42405D76Q33892278-BC10BC05-AD47-4E99-8C45-71B04A7C8021Q33963837-66B4115E-26A8-46FD-9DA5-8E0BD4355F64Q34227712-358A08A8-1542-4843-9240-BC27836227FCQ34392470-5EEF33AA-2998-4D40-978B-0D7006E28DCCQ34654728-BDB7F2BD-6B93-4DE0-9DE9-2493D7F2FC71Q34786452-A39C10DA-10CC-4747-B2B4-EBDE71F49CB2Q35176432-54EB1686-1261-4AF1-BF35-04A7E27B6E95Q35230282-6FD17B59-4381-41E8-B9DD-434B12914516Q35463820-A49147C9-48C7-493B-8786-EE113ECD5F53Q35572415-5D386A65-B8BE-4B54-9BA0-A03F46638809Q35626776-61D2BAF0-CDC2-4A37-AD48-9E0686FE2C37Q35644324-17D0B041-DE7E-42B1-9DDB-A7079B6B23BBQ35740772-7AD9AF60-2FE2-4882-B9CB-82391386F52EQ35741518-10C6FDA1-7A2B-4EC6-B351-212C96CF7AC8Q35748636-55AAEC88-4E49-4E1E-8BB9-68BEF7673A2DQ35753931-6A5C55F7-3F1C-48C2-887C-A5843AEA16BE
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antiangiogenic therapy and tumor progression.
@ast
Antiangiogenic therapy and tumor progression.
@en
type
label
Antiangiogenic therapy and tumor progression.
@ast
Antiangiogenic therapy and tumor progression.
@en
prefLabel
Antiangiogenic therapy and tumor progression.
@ast
Antiangiogenic therapy and tumor progression.
@en
P1433
P1476
Antiangiogenic therapy and tumor progression.
@en
P356
10.1016/S1535-6108(03)00336-2
P577
2004-01-01T00:00:00Z